Abstract
Richard Parker-Manuel, PhD, is a Group Leader for Plasmid Engineering and Production at OXGENE, A WuXi Advanced Therapies Company. He has twenty years’ experience in molecular biology with nearly seven years in the cell and gene therapy space. He oversees the design and engineering of adeno associated virus and lentivirus vector plasmids for a variety of clients. He is also involved in several R&D initiatives with the aim of making OXGENE’s excellent vectors even better.Qian Liu, PhD, joined OXGENE in July 2017 as a Cell Line Engineering Scientist. She has a background in cell and molecular biology, She was then gradually promoted to lead all biomanufacturing services OXGENE provide. Prior to joining OXGENE, Qian was a postdoctoral researcher in the field of Regenerative Medicine, involved in bioartificial liver development and stem cell differentiation mechanism investigation in Loughborough University and the University of Nottingham, respectively. Qian obtained her PhD in Molecular Nutrition from the University of Nottingham.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
